Tearsheet
Investment Highlights Market Valuation Price Chart Return vs. Risk About ALNY Interactive Breakdown Better Bets vs. ALNY Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Alnylam Pharmaceuticals (ALNY)

Market Price (10/26/2025): $461.59 | Market Cap: $59.9 Bil
Sector: Health Care | Industry: Biotechnology

Alnylam Pharmaceuticals (ALNY)

Market Price (10/26/2025): $461.59
Market Cap: $59.9 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0 Low stock price volatility
Vol 12M is 44%		  Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -115 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -4.9%
1   Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1.9%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -3.2%
2   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.0%
0 Low stock price volatility
Vol 12M is 44%
1 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -115 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -4.9%
2 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1.9%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -3.2%
3 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.0%

Market Valuation & Key Metrics

ALNYS&P 500
REVENUE GROWTHVERY GOOD
Rev LTM ($ Bil)2.3
Rev Chg Q20.2%6.4%
Rev Chg LTM17.2%5.3%
Rev Chg 3Y Avg40.8%5.4%
PROFITABILITYVERY POOR
Op Inc LTM ($ Bil)-0.1
CFO LTM ($ Bil)-0.0
Net Inc LTM ($ Bil)-0.3
Op Mgn LTM-4.9%18.7%
CFO/Rev LTM-1.9%20.4%
Net Inc Mgn-11.5%12.7%
VALUATIONVERY HIGH
P/S25.53.3
P/CFO-1,326.916.1
P/FCF-794.020.9
P/E-221.924.0
STABILITYVERY GOOD
Debt/Equity0.020.21
Cash/Assets0.620.07

ALNY Stock

   
   
   
   
   
   
   

Return vs. Risk

Price Returns Compared

 202020212022202320242025Total [1]
Returns
ALNY Return13%30%40%-19%23%97%302%
Peers Return42%-3%-13%-12%-10%19%12%
S&P 500 Return16%27%-19%24%23%15%110%

Monthly Win Rates [3]
ALNY Win Rate58%50%58%50%33%78% 
Peers Win Rate35%32%43%38%27%56% 
S&P 500 Win Rate58%75%42%67%75%67% 

Max Drawdowns [4]
ALNY Max Drawdown-19%-2%-29%-36%-25%-5% 
Peers Max Drawdown-39%-34%-35%-33%-35%-48% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 

[1] Cumulative total returns since the beginning of 2020
[2] Peers: IONS, NTLA, SRPT, APM, BBOT. See ALNY Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/24/2025 (YTD)

How Low Can It Go

Unique KeyEventALNYS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-42.5%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven73.8%34.1%
2022 Inflation ShockTime to BreakevenTime to Breakeven84 days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-30.5%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven43.9%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven36 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-57.8%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven137.0%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven543 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-58.6%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven141.4%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven1577 days1480 days

Compare to IONS, NTLA, SRPT, APM, BBOT


In The Past

Alnylam Pharmaceuticals's stock fell -42.5% during the 2022 Inflation Shock from a high on 10/14/2021. A -42.5% loss requires a 73.8% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Alnylam Pharmaceuticals (ALNY)

Better Bets than Alnylam Pharmaceuticals (ALNY)

 ALNYBetter Performance than ALNY
MetricValueIndustry (Biotechnology)
Rev Chg LTM17.2%INSM (21.2%), UTHR (17.6%), INCY (18.9%), NBIX (21.7%), BMRN (18.4%)
Rev Chg 3Y Avg40.8%BBIO (1225.0%), RYTM (137.5%), CYTK (824.6%), AXSM (699.5%), CRSP (380.7%)
Op Mgn LTM-4.9%ABBV (23.5%), AMGN (23.5%), GILD (37.4%), VRTX (-1.7%), REGN (27.0%)
CFO/Rev LTM-1.9%ABBV (33.1%), AMGN (34.4%), GILD (34.2%), VRTX (33.7%), REGN (33.4%)
FCF/Rev LTM-3.2%ABBV (31.3%), AMGN (30.4%), GILD (32.5%), VRTX (30.6%), REGN (25.0%)
Total Yield-0.4%ABBV (3.7%), AMGN (7.4%), GILD (6.8%), VRTX (3.4%), REGN (7.6%)
 ALNYBetter Performance than ALNY
MetricValueAll Other Sectors
Rev Chg LTM17.2%NVDA (71.6%), META (19.4%), AVGO (28.0%), PLTR (38.8%), AMD (27.2%)
Rev Chg 3Y Avg40.8%NVDA (92.0%), RCL (65.4%), NU (70.1%), APO (129.8%), RDDT (42.6%)
Op Mgn LTM-4.9%NVDA (58.1%), AAPL (31.9%), MSFT (45.6%), GOOGL (32.7%), AMZN (11.4%)
CFO/Rev LTM-1.9%NVDA (46.6%), AAPL (26.6%), MSFT (48.3%), GOOGL (36.0%), AMZN (18.1%)
FCF/Rev LTM-3.2%NVDA (43.6%), AAPL (23.5%), MSFT (25.4%), GOOGL (18.0%), AMZN (2.0%)
Total Yield-0.4%NVDA (1.9%), AAPL (2.9%), MSFT (3.2%), GOOGL (4.0%), AMZN (3.0%)
 Best Bets In Health Care Sector
 ALNYRPRX HALO CPRX LNTH PBH EW AVTR ILMN HCA THC
What You Pay           
P/E-222.815.514.412.314.214.510.815.312.517.912.9
P/EBIT-286.08.211.310.59.79.326.610.410.49.85.0
What You Get           
Rev Chg Q20.2%7.7%40.8%19.4%-4.1%-6.6%11.9%-1.1%-4.8%6.4%3.2%
Rev Chg LTM17.2%3.0%35.0%28.5%5.7%0.6%9.1%-2.3%-3.3%6.4%-1.1%
Rev Chg 3Y Avg40.8%0.8%35.5%49.9%34.3%0.8%3.0%-4.3%-3.0%6.6%2.7%
FCF/Rev 3Y Avg-16.6%113.4%43.4%38.9%26.1%21.6%11.9%9.7%9.0%8.4%7.1%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Alnylam Pharmaceuticals Earnings Notes  
2How Low Can Alnylam Pharmaceuticals Stock Really Go?Return 
3Now Is Not The Time To Buy Alnylam Pharmaceuticals StockBuy or Fear 
4Day 5 of Gains Streak for Alnylam Pharmaceuticals Stock with 29% Return (vs. 78% YTD) [8/4/2025]Notification 
5ALNY Dip Buy Analysis  
6Alnylam Pharmaceuticals Market PriceMarket Price 
7Alnylam Pharmaceuticals Total Shareholder Return (TSR): 22.9% in 2024 and 11.5% 3-yr compounded annual returns (above peer average)  
8Alnylam Pharmaceuticals (ALNY) Operating Cash Flow ComparisonFinancials 
9Alnylam Pharmaceuticals (ALNY) Net Income ComparisonFinancials 
10Alnylam Pharmaceuticals (ALNY) Operating Income ComparisonFinancials 
11ARTICLES  
12Now is not the time to buy Alnylam Pharmaceuticals stock August 21st, 2025
13Large Cap Stocks Trading At 52-Week High August 19th, 2025
14Large Cap Stocks Trading At 52-Week High August 7th, 2025
15ALNY Stock Up 29% after 5-Day Win Streak August 5th, 2025
16ALNY Stock in Focus: Does It Outshine the Peer Group? August 1st, 2025
Title
0DASHBOARDS
1Now is not the time to buy Alnylam Pharmaceuticals stock
2Large Cap Stocks Trading At 52-Week High
3Large Cap Stocks Trading At 52-Week High
4ALNY Stock Up 29% after 5-Day Win Streak
5ALNY Stock in Focus: Does It Outshine the Peer Group?
6ARTICLES
7Alnylam Pharmaceuticals Earnings Notes
8How Low Can Alnylam Pharmaceuticals Stock Really Go?
9Now Is Not The Time To Buy Alnylam Pharmaceuticals Stock
10Day 5 of Gains Streak for Alnylam Pharmaceuticals Stock with 29% Return (vs. 78% YTD) [8/4/2025]
11ALNY Dip Buy Analysis
12Alnylam Pharmaceuticals Market Price
13Alnylam Pharmaceuticals Total Shareholder Return (TSR): 22.9% in 2024 and 11.5% 3-yr compounded annual returns (above peer average)
14Alnylam Pharmaceuticals (ALNY) Operating Cash Flow Comparison
15Alnylam Pharmaceuticals (ALNY) Net Income Comparison
16Alnylam Pharmaceuticals (ALNY) Operating Income Comparison

Trade Ideas

Select past ideas related to ALNY. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		3.5%3.5%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		2.8%2.8%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		6.4%6.4%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		19.5%19.5%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		17.1%17.1%-8.0%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		3.5%3.5%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		2.8%2.8%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		6.4%6.4%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		19.5%19.5%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		17.1%17.1%-8.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1VICRVicor57.5%87.2%
2INBXInhibrx Biosciences53.8%272.0%
3CLBCore Laboratories48.7%-2.4%
4BALYBallys46.2%6.8%
5MOFGMidWestOne Financial43.2%39.2%
6NUVBNuvation Bio42.2%82.3%
7CLOVClover Health Investments41.0%21.3%
8CELCCelcuity36.6%442.2%
9WGOWinnebago Industries33.6%-12.7%
10GTXGarrett Motion33.3%91.3%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-45.4%8328.6%
2ITGRInteger-30.4%-45.0%
3METCRamaco Resources-23.8%244.9%
4WRLDWorld Acceptance-18.6%25.6%
5ASMAvino Silver & Gold Mines-18.2%450.5%
6SESSES AI-17.6%15.5%
7SMPLSimply Good Foods-17.5%-48.0%
8TNGXTango Therapeutics-17.0%142.6%
9OKLOOklo-16.7%540.8%
10LENZLENZ Therapeutics-16.4%10.7%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1WOLFWolfspeed1498.4%344.0%
2PRAXPraxis Precision Medicines253.2%126.1%
3NVTSNavitas Semiconductor116.1%294.1%
4SNDKSanDisk97.4% 
5UAMYUnited States Antimony90.3%578.5%
6GRALGRAIL85.2%400.8%
7BALYBallys82.9%6.8%
8ORKAOruka Therapeutics81.1%40.5%
9INBXInhibrx Biosciences79.9%272.0%
10CIFRCipher Mining77.2%345.3%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1VGVenture Global-35.7% 
2PMIPicard Medical-35.3%8328.6%
3SOCSable Offshore-33.7%-41.7%
4FWRDForward Air-28.9%-39.0%
5FLYFirefly Aerospace-28.5% 
6ITGRInteger-28.4%-45.0%
7USNAUsana Health Sciences-26.5%-42.0%
8HTZHertz Global-26.3%41.5%
9RCReady Capital-25.1%-50.3%
10ULHUniversal Logistics-24.8%-61.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1VICRVicor57.5%87.2%
2INBXInhibrx Biosciences53.8%272.0%
3CLBCore Laboratories48.7%-2.4%
4BALYBallys46.2%6.8%
5MOFGMidWestOne Financial43.2%39.2%
6NUVBNuvation Bio42.2%82.3%
7CLOVClover Health Investments41.0%21.3%
8CELCCelcuity36.6%442.2%
9WGOWinnebago Industries33.6%-12.7%
10GTXGarrett Motion33.3%91.3%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-45.4%8328.6%
2ITGRInteger-30.4%-45.0%
3METCRamaco Resources-23.8%244.9%
4WRLDWorld Acceptance-18.6%25.6%
5ASMAvino Silver & Gold Mines-18.2%450.5%
6SESSES AI-17.6%15.5%
7SMPLSimply Good Foods-17.5%-48.0%
8TNGXTango Therapeutics-17.0%142.6%
9OKLOOklo-16.7%540.8%
10LENZLENZ Therapeutics-16.4%10.7%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Alnylam Pharmaceuticals

Financials

ALNYIONSNTLASRPTAPMBBOTMedian
NameAlnylam .Ionis Ph.Intellia.Sarepta .Aptorum BridgeBi. 
Mkt Price463.4370.8625.6022.811.4910.9624.20
Mkt Cap60.111.22.72.2--7.0
Rev LTM2,348717532,482-0717
Op Inc LTM-115-472-512-1--93-115
FCF LTM-75-563-422-454--60-422
FCF 3Y Avg-184-438-396-505---417
CFO LTM-45-502-419-301--60-301
CFO 3Y Avg-131-401-387-395---391

Growth & Margins

ALNYIONSNTLASRPTAPMBBOTMedian
NameAlnylam .Ionis Ph.Intellia.Sarepta .Aptorum BridgeBi. 
Rev Chg LTM17.2%-7.6%15.0%64.9%--16.1%
Rev Chg 3Y Avg40.8%-1.4%6.2%45.0%--23.5%
Rev Chg Q20.2%10.1%104.8%68.4%--44.3%
QoQ Delta Rev Chg LTM4.4%1.7%16.0%11.1%--7.8%
Op Mgn LTM-4.9%-65.9%-968.7%-0.0%---35.4%
Op Mgn 3Y Avg-27.5%-65.7%-991.9%-16.1%---46.6%
QoQ Delta Op Mgn LTM3.0%1.5%218.7%5.2%--4.1%
CFO/Rev LTM-1.9%-70.0%-791.9%-12.1%---41.0%
CFO/Rev 3Y Avg-13.1%-59.0%-766.0%-29.1%---44.0%
FCF/Rev LTM-3.2%-78.5%-798.0%-18.3%---48.4%
FCF/Rev 3Y Avg-16.6%-64.4%-785.0%-35.5%---50.0%

Valuation

ALNYIONSNTLASRPTAPMBBOTMedian
NameAlnylam .Ionis Ph.Intellia.Sarepta .Aptorum BridgeBi. 
Mkt Cap60.111.22.72.2--7.0
P/S25.615.750.20.9--20.6
P/EBIT-286.0-29.8-5.2-446.5---157.9
P/E-222.8-24.6-5.5-38.6---31.6
P/CFO-1,332.2-22.4-6.3-7.4---14.9
Total Yield-0.4%-4.1%-18.1%-2.6%---3.3%
Dividend Yield0.0%0.0%0.0%0.0%--0.0%
FCF Yield 3Y Avg-0.8%-7.0%-23.9%-12.0%---9.5%
D/E0.00.10.00.6--0.1
Net D/E-0.0-0.1-0.10.2---0.0

Returns

ALNYIONSNTLASRPTAPMBBOTMedian
NameAlnylam .Ionis Ph.Intellia.Sarepta .Aptorum BridgeBi. 
1M Rtn3.1%12.5%54.1%28.7%-16.8%-7.3%7.8%
3M Rtn40.9%67.7%88.3%91.2%-17.7%-67.7%
6M Rtn84.2%138.6%208.1%-62.3%53.6%-84.2%
12M Rtn62.7%80.8%60.5%-82.6%-9.7%-60.5%
3Y Rtn130.5%59.8%-51.3%-80.0%-77.3%--51.3%
1M Excs Rtn0.2%9.7%51.3%25.9%-19.6%-10.1%5.0%
3M Excs Rtn36.4%65.8%89.0%58.3%-13.7%-58.3%
6M Excs Rtn61.3%115.7%185.1%-85.2%30.7%-61.3%
12M Excs Rtn40.2%67.1%5.4%-98.3%-28.9%-5.4%
3Y Excs Rtn57.6%-24.5%-135.2%-163.5%-164.2%--135.2%

Financials

$ Mil | FY: 12/312025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q2
Period End3/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/20226/30/2022
Filing Date5/1/20252/13/202510/31/20248/1/20245/2/20242/15/202411/2/20238/3/20235/4/20232/23/202310/27/20227/28/2022
Key Financials Quarterly            
Total Revenue594593501660494440751319319335264225
Ebitda11-155-4759-15-106205-221-117-177-344-212
Operating Income18-105-7749-43-116214-230-150-189-258-192
Net Income-57-84-112-17-66-138148-276-174-207-406-277
EPS-0.44-0.65-0.87-0.13-0.52-1.101.18-2.21-1.40-1.68-3.32-2.29
Key Financials TTM            
Total Revenue TTM2,3482,2482,0952,3442,0031,8281,7241,2371,1431,037961884
Ebitda TTM-132-158-110143-137-239-310-859-850-910-935-732
Operating Income TTM-115-177-188103-176-282-354-826-788-785-791-715
Net Income TTM-270-278-332-73-332-440-510-1,064-1,065-1,131-1,182-981
Growth Rates Quarterly            
Total Revenue Growth20.2%34.9%-33.3%107.0%54.8%31.2%184.0%41.8%49.7%29.6%40.9%1.9%
EBITDA Growth177.3%-45.7%-123.0%126.6%87.4%40.0%159.6%-4.2%33.8%12.3%-144.6%-72.9%
Operating Income Growth141.6%9.7%-136.0%121.2%71.0%38.3%182.9%-19.9%-2.1%3.1%-42.0%-31.1%
Net Income Growth12.8%39.2%-175.5%93.9%62.1%33.6%136.4%0.5%27.6%19.7%-98.5%-46.3%
Margins Quarterly            
EBITDA Margin1.9%-26.1%-9.4%8.9%-3.0%-24.2%27.3%-69.2%-36.7%-52.9%-130.2%-94.2%
Operating Income Margin3.0%-17.7%-15.4%7.4%-8.8%-26.5%28.5%-72.1%-46.9%-56.3%-97.6%-85.3%
Net Income Margin-9.7%-14.1%-22.3%-2.6%-13.3%-31.4%19.7%-86.6%-54.5%-61.9%-153.6%-123.4%
Cash & Debt            
Total Cash2,6322,6952,7802,6252,3712,4392,4062,0582,0712,1922,2652,111
Total Debt1,3021,2961,3021,3041,3011,3051,3091,3141,3201,3201,324991
Net Debt / (Cash)-1,331-1,398-1,478-1,321-1,070-1,134-1,097-743-750-872-941-1,120
Cash Flows Quarterly            
FCF from Operations-118-9544124-82-30359-59-166-132-115-123
Cash Flows TTM            
FCF from Operations TTM-45-8573721891042-473-537-541-559-578
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC1.2%-3.0%-5.3%3.4%-3.0%-8.2%15.0%-15.7%-10.5%-13.6%-19.3%-15.3%
Return on Invested Capital (ROIC) TTM            
ROIC TTM-1.4%-2.2%-3.3%1.8%-3.0%-5.0%-6.3%-14.1%-13.7%-14.2%-14.8%-14.3%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
AMVUTTRA558940  
Net revenues from collaborations54613518113153
ONPATTRO355558475306166
GIVLAARI219173128550
OXLUMO11070600 
Royalty revenue4181  
Total1,8281,037844493220


Price Behavior

ALNY Betas & Captures as of 9/30/2025

 1M2M3M6M1Y3Y
Beta0.860.180.040.900.990.91
Up Beta-1.81-0.59-0.670.780.790.89
Down Beta-0.45-0.84-0.861.191.161.22
Up Capture120%120%156%126%150%61%
Bmk +ve Days13233574144420
Stock +ve Days12263976130373
Down Capture183%3%-78%46%95%91%
Bmk -ve Days8192952107330
Stock -ve Days9162449120376

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date10152025
Short Interest: Shares Quantity3,993,922
Short Interest: % Change Since 930202513.9%
Average Daily Volume1,146,101
Days-to-Cover Short Interest3.48
Basic Shares Quantity129,676,000
Short % of Basic Shares3.1%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
7/31/202515.4%26.0%33.1%
2/15/2024-10.2%-0.8%-9.1%
11/2/20232.9%7.9%9.2%
8/3/20231.7%-0.3%5.8%
5/4/20233.0%5.7%-2.9%
1/9/2023-2.3%4.7%-1.8%
10/27/2022-3.5%6.6%5.8%
7/28/20221.1%49.3%50.7%
...
SUMMARY STATS   
# Positive10119
# Negative10911
Median Positive2.3%6.6%13.2%
Median Negative-3.7%-7.5%-6.6%
Max Positive15.4%49.3%50.7%
Max Negative-15.2%-9.6%-18.9%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025731202510-Q 6/30/2025
3312025501202510-Q 3/31/2025
12312024213202510-K 12/31/2024
93020241031202410-Q 9/30/2024
6302024801202410-Q 6/30/2024
3312024502202410-Q 3/31/2024
12312023215202410-K 12/31/2023
93020231102202310-Q 9/30/2023
6302023803202310-Q 6/30/2023
3312023504202310-Q 3/31/2023
12312022223202310-K 12/31/2022
93020221027202210-Q 9/30/2022
6302022728202210-Q 6/30/2022
3312022428202210-Q 3/31/2022
12312021210202210-K 12/31/2021
93020211028202110-Q 9/30/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0Tanguler TolgaEVP, Chief Commercial Officer9022025Sell445.5319586,87813,041,109Form
1Reitan Colleen F 5122025Buy286.00329,1529,152Form
2Garg PushkalCMO & EVP Dev & Med Affairs3252025Sell285.004,3211,231,4855,762,985Form
3Fitzgerald Kevin JosephCSO & EVP, Head of Research3032025Sell236.51276,3863,040,100Form
4Garg PushkalCMO & EVP Dev & Med Affairs12132024Sell247.4812129,9454,290,313Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.